Narcolepsy Market Size Worth USD 4,537.9 million by 2027 and is expected to grow at a CAGR of 9.5%: The Insight Partners

According to The Insight Partners' research, the global narcolepsy market is expected to reach US$ 4,537.9 million in 2027 from US$ 2,026.8 in 2018. The market is estimated to grow at a CAGR of 9.5% from 2019 to 2027. Rising prevalence of sleep-related neurological disorders, emerging local pharmaceutical and biopharmaceutical companies, and increasing awareness regarding neurological disorders are the key growth stimulants for market expansion.

According to the National Institute of Health (NIH), approximately 40 million Americans suffer from neurological diseases in the US, whereas around 20 million people experience occasional sleeping problems. Over the last decades, we have known a lot about the pathophysiology of narcolepsy. According to the National Center for Biotechnology Information, the prevalence of narcolepsy with cataplexy has been examined in many studies and falls between 25 and 50 per 100,000 people.

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis - https://www.theinsightpartners.com/sample/TIPRE00003326/?utm_source=OpenPR&utm_medium=10408

Sleep disorders are common in both men and women. However, essential disparities in the prevalence and severity of specific sleep disorders have been identified in minorities and underserved populations. More than 50 million Americans already suffer from over 80 different sleep disorders, and another 20-30 million suffer intermittent sleep problems each year.

Based on type, the global narcolepsy marketplace is divided into narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary narcolepsy. Among these, the narcolepsy with cataplexy segment held 65.1% of the market share in 2018. The segment was valued at US$ 1,319.6 million in 2018 and is anticipated to reach US$ 3,021.4 million by 2027, expanding at 9.7% CAGR over 2019-2027.

Have a 15-minute-long discussion with the lead analyst and author of the report in a time slot decided by you. You will be briefed about the contents of the report and queries regarding the scope of the document will be addressed as well - https://www.theinsightpartners.com/speak-to-analyst/TIPRE00003326?utm_source=OpenPR&utm_medium=10408

Speaking of product gamut, the industry is split into central nervous system (CNS) stimulants, sodium oxybate, and antidepressants. Among these, the sodium oxybate segment held 46.2% of the market share in 2018. The segment was evaluated at US$ 935.6 million in 2018 and is anticipated to reach US$ 2,160.5 million by 2027. The growth rate of this segment is projected to be 9.8% over 2019-2027.

As per the distribution channel, the business sphere is arrayed into hospital and retail pharmacies. Among these, the hospital pharmacies segment held 87.9% of the market share in 2018. The segment was valued at US$ 1,782.1 million in 2018 and is anticipated to reach US$ 4,066.1 million by 2027, expanding at 9.7% CAGR throughout.
From the regional frame of reference, the Asia Pacific narcolepsy market is expected to grow at the highest rate during the forecast period owing to a higher number of R&D and increasing investments in sleep-related neurological disorders. In addition, the emergence of new local players with a competitive drug portfolio is expected to fuel market expansion in Asia Pacific. The market for narcolepsy in Asia Pacific is expected to reach US$ 526.4 million by 2027 from US$ 224.8 million in 2018 by expanding at 10% CAGR over the analysis period.

Leading companies formulating the competitive landscape of the global narcolepsy market are Teva Pharmaceutical Industries Limited, Jazz Pharmaceuticals PLC, Arena Pharmaceuticals Inc., Graymark Healthcare Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Mylan N.V., Bioprojet Pharma SAS, Shionogi & Co. Ltd., and Ligand Pharmaceuticals Inc.

Schedule A Pre-Sale Discussion with The Author Team in A Slot That You Prefer to Address Queries on Scope of The Study, Customization, Introduction to Research Methodology, Assistance on Technologies and Market Definitions: https://www.theinsightpartners.com/inquiry/TIPRE00003326/?utm_source=OpenPR&utm_medium=10408

• In January 2019, Shionogi & Co., Ltd. entered into a collaborative research agreement with PeptiDream Inc. to discover and develop multiple peptide drug-conjugates (PDCs), including cargo peptides, to improve migration of drugs to the brain.
• In January 2018, Takeda Pharmaceutical Company Limited and Denali Therapeutics Inc. entered into a strategic option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases.
• In October 2018, Jazz Pharmaceuticals plc received FDA approval for its supplemental new drug application (sNDA) to revise labeling for Xyrem.
• In September 2018, Takeda Pharmaceutical Company Limited and H. Lundbeck applied for a new drug application (NDA) to the Ministry of Health, Labour and Welfare in Japan for vortioxetine to treat Major Depressive Disorder (MDD) in adults.

Contact US:
If you have any queries about this report or would like further information, please contact us:
North America: +1 646 491 9876
Asia-Pacific: +91 20 6727 8686
Email: sales@theinsightpartners.com

ABOUT US:
The Insight Partners is a one stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Our research model is very simple. We believe in client servicing and delivering best quality to our customers. Through our research content, we are making sure that our customers get value of their money along with better quality data and analysis.
Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis etc. We provide detailed break-up of segmentation in terms of geography, technology, product and services etc.; which helps our clients to get a deeper analysis on various research topics.

This release was published on openPR.